Bunkerhill AVC vs Lung AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill AVC

by BunkerHill Health

Lung AI

by Exo

AI Verdict

These tools are adjacent competitors, both leveraging AI in cardiology and radiology, but with distinct approaches. Bunkerhill AVC focuses on automated detection and quantification of calcifications from CT scans, integrating with existing EHRs for workflow automation. In contrast, Lung AI by Exo utilizes a handheld ultrasound platform with on-device AI for real-time detection of conditions like pleural effusion and consolidation, emphasizing point-of-care diagnostics.

Choose Bunkerhill AVC if…

Choose Bunkerhill AVC if your healthcare system primarily utilizes chest CT scans and seeks to opportunistically detect and quantify aortic valve calcification (AVC) in adult patients aged 40 and above. This tool integrates with existing EHRs and clinical archives to automate workflows for early detection and potential proactive management of aortic stenosis.

View Bunkerhill AVC →

Choose Lung AI if…

Choose Lung AI if your clinical setting requires a portable, real-time diagnostic solution for lung and cardiac conditions, especially in emergency medicine or point-of-care scenarios. This handheld ultrasound device with on-device AI can quickly detect pleural effusion, consolidation/atelectasis, and provide automated indicators for cardiac conditions, even with less-than-perfect scans.

View Lung AI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill AVC	Lung AI
Pricing	Contact for pricing	Contact for pricing
Deployment	Integrates with full Electronic Health Records (EHRs) and clinical archives within health systems.	On-device (integrated with Exo Iris handheld ultrasound device)
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	1 AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool B (Lung AI) is integrated with a handheld ultrasound device (Exo Iris) and offers on-device AI processing, allowing for real-time feedback and guided image capture, which significantly enhances ease of use at the point of care, especially for less experienced users. Tool A (Bunkerhill AVC) integrates with existing EHRs and clinical archives, which is beneficial for workflow, but its generative AI platform for clinical reasoning and action, while powerful, may have a steeper learning curve for full utilization.

Clinical Value

Bunkerhill AVC

Tool A (Bunkerhill AVC) offers FDA-cleared algorithms for the early detection and quantification of aortic valve calcification, coronary artery calcification, and mitral annular calcification from CTs, as well as opportunistic bone density assessment. This provides a broad range of critical diagnostic insights from routine imaging. Tool B (Lung AI) focuses on AI-powered detection of pleural effusion and consolidation/atelectasis from handheld ultrasound, which is valuable for real-time decision-making, but its scope of conditions is narrower.

Pricing & Value

Tie

Both tools require contacting the company for pricing, making direct comparison difficult. While Bunkerhill Health has secured a national billing code and associated payment for its cardiovascular analysis, which can improve reimbursement for health systems, the overall value proposition for each tool would depend on specific institutional needs and existing infrastructure.

Enterprise Readiness

Bunkerhill AVC

Tool A (Bunkerhill AVC) is part of the broader Carebricks platform, designed for integration with full EHRs and clinical archives, enabling customizable AI agents for diverse workflows and system-wide deployment. This indicates a strong focus on enterprise-level integration and scalability. Tool B (Lung AI)'s on-device deployment is excellent for point-of-care, but its enterprise readiness for large-scale data management and diverse clinical workflows across an entire health system is not as explicitly detailed.

Innovation

Bunkerhill AVC

Tool A (Bunkerhill AVC) leverages generative AI for clinical reasoning and action, allowing for automated workflows and customizable AI agents, which represents a highly innovative approach to healthcare AI. Its FDA clearance for detecting and quantifying aortic valve calcification on non-gated, non-contrast chest CTs, and later on contrast-enhanced CTs, highlights pioneering advancements in opportunistic screening. Tool B (Lung AI) is innovative in its application of AI to handheld ultrasound for real-time diagnostics, but generative AI capabilities are not specified.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the depth or accessibility of support and documentation for either Bunkerhill AVC or Lung AI. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill AVC	Lung AI
Tool Name	Bunkerhill AVC	Lung AI
Company	BunkerHill Health	Exo
Tagline	Generative AI for clinical reasoning and action.	Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning.
Key Feature Focus	Automated detection and quantification of aortic valve calcification (Bunkerhill AVC)	AI-powered detection of pleural effusion
Specialties	Cardiology, Radiology	Cardiology, Emergency Medicine, Pulmonology

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill AVC and Lung AI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows, and what is the learning curve for physicians?

Bunkerhill AVC integrates with full EHRs and clinical archives, automating workflows for early detection and quantification of aortic valve calcification from chest CTs. It aims to highlight patients who may warrant further evaluation for aortic stenosis and coordinate next steps, with an optional manual review. Exo Lung AI, integrated with the handheld Exo Iris ultrasound device, provides real-time AI-powered detection of pleural effusion and consolidation/atelectasis. Its guided image capture and real-time feedback (SweepAI) are designed to simplify the process for both early POCUS users and seasoned experts, potentially reducing the learning curve for acquiring and interpreting images.

What is the accuracy and sensitivity of each tool for its stated purpose?

Bunkerhill AVC was validated in a retrospective study across 33 sites, demonstrating precision of 0.826 and recall of 0.855 for region of interest detection, with performance comparable to a predicate device. Exo Lung AI has shown high accuracy in detecting pleural effusion (sensitivity 0.967, specificity 0.912) and consolidation/atelectasis (sensitivity 0.968, specificity 0.945) in a multi-reader, multi-case study. It also achieved a sensitivity of 91% and specificity of 81% for A-line detection, and 84% sensitivity and 86% specificity for B-line detection.

Beyond the listed specialties, are there any specific clinical contexts where one tool would be more advantageous than the other?

Bunkerhill AVC is particularly advantageous in cardiology and radiology for opportunistic screening of aortic valve calcification from routine chest CTs, aiding in early detection of aortic stenosis. Exo Lung AI is highly beneficial in emergency medicine and pulmonology, especially at the point of care, for rapid, real-time assessment of lung conditions like pleural effusion and consolidation/atelectasis, which can be critical for immediate patient management.

What kind of support and training are available to ensure effective utilization and address any issues?

Exo offers Exo U, an AI-powered POCUS education and training platform, which suggests a focus on user education to facilitate effective utilization. Bunkerhill Health's Carebricks platform allows health systems to design and deploy customizable AI agents, implying a level of support for tailoring the tool to specific needs.

How do these tools contribute to a faster time-to-value for a healthcare system?

Bunkerhill AVC aims to accelerate the identification of patients at risk for aortic stenosis from existing CT scans, potentially leading to earlier intervention and improved outcomes. Exo Lung AI provides real-time diagnostic information at the point of care, which can significantly reduce diagnostic error and accelerate patient care pathways, leading to faster treatment or discharge.

What audit-trail features are available to track AI-assisted findings and physician interactions?

While specific audit-trail features are not detailed for either tool, Bunkerhill AVC's integration with EHRs and its role in coordinating next steps with optional manual review suggest a system for tracking actions and decisions. Exo's emphasis on transparency and the clinician remaining in control, with the ability to see and verify data, implies a focus on auditable processes.